Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 11/20 | 0.47 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | FABP2 | P12104 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341919 | 0.86 | KDM4E (0.52) | MAP2K1FTOFABP4GRIK1MEN1 | |
| SCHEMBL3427476 | 0.86 | PTGS2 (0.46) | MAP2K1CLCN2MEN1PTGS2KMT2A | |
| SCHEMBL13841944 | 0.84 | MEN1 (0.60) | MAP2K1FTOFABP4TTRMEN1 | |
| SCHEMBL4856761 | 0.83 | MAP2K1 (0.70) | MAP2K1 | |
| SCHEMBL6944105 | 0.83 | MAP2K1 (0.47) | MAP2K1FTOFABP3FABP4CLCN2 | |
| SCHEMBL6950981 | 0.80 | MAP2K1 (0.47) | MAP2K1FTOCLCN2MEN1KMT2A | |
| SCHEMBL3867085 | 0.80 | FTO (0.47) | MAP2K1FTOFABP3FABP4CLCN2 | |
| SCHEMBL6951081 | 0.79 | LMNA (0.48) | MAP2K1LMNAMAPT | |
| SCHEMBL15129554 | 0.79 | CLCN2 (0.47) | MAP2K1FTOFABP3FABP4CLCN2 | |
| SCHEMBL17982597 | 0.78 | FTO (0.46) | MAP2K1FTOFABP3FABP4CLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937158-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2018-04-10 | — | — | US | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | disclosed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | disclosed |
| EP-2804855-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | Tianjin Binjiang Pharma, Inc. (CN) | 2014-11-26 | — | — | EP | disclosed |
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1689233-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1673339-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051302-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 94/4885FTO 4017/4885FABP3 4875/4885 |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, CDK1, MAP3K1 | MAP2K1 436/4885FTO 4551/4885FABP3 4749/4885 |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 92/4885FTO 3568/4885FABP3 4867/4885 |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 92/4885FTO 3867/4885FABP3 4763/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 92/4885FTO 3568/4885FABP3 4867/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | MAP2K1 4674/4885FTO 3381/4885FABP3 587/4885 |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, MAPK1, BDKRB1 | MAP2K1 393/4885FTO 4408/4885FABP3 4799/4885 |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 33/4885FTO 4341/4885FABP3 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.